IntelyCare, Inc. provides on-demand staffing services tailored for healthcare organizations, focusing primarily on post-acute care facilities. Established in 2014 and headquartered in Quincy, Massachusetts, the company offers a digital workforce augmentation platform that combines a gig-model application with advanced data science. This platform allows healthcare facilities to optimize staffing levels by efficiently matching nursing professionals with available shifts, thereby addressing the growing gap between workforce supply and demand. Nurses and nursing assistants benefit from the platform by having the flexibility to create their own schedules and select shifts that suit them, promoting a more engaged and productive workforce. IntelyCare serves a variety of clients, including home care agencies, assisted living facilities, long-term care facilities, and rehabilitation hospitals. As a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC, IntelyCare is positioned to revolutionize the healthcare staffing market by filling nursing shifts at a rate three times higher than the industry average.
LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation.
The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
Endeavor BioMedicines is a clinical-stage company focused on creating innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). The company is developing a small-molecule inhibitor aimed at addressing the underlying causes of this disease. This potential therapy not only seeks to halt the progression of IPF but may also reverse its effects, thereby providing healthcare professionals with precision treatment options for this terminal condition. By targeting the root causes of the disease, Endeavor BioMedicines aims to improve patient outcomes and enhance quality of life for those affected by pulmonary fibrosis.
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.
Quanta Therapeutics
Series C in 2021
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
Lexeo Therapeutics is a clinical-stage biotechnology company specializing in genetic medicines. The company develops adeno-associated virus (AAV)-mediated therapies, primarily in collaboration with Weill Cornell Medicine’s Department of Genetic Medicine. Its pipeline includes treatments for both rare and non-rare monogenic diseases, as well as hereditary and acquired conditions. Lexeo Therapeutics aims to address high unmet medical needs across various patient populations, focusing on both preclinical and clinical gene therapy candidates. The company is committed to advancing its clinical programs towards commercialization while maintaining research partnerships to enhance its preclinical pipeline.
Sydnexis specializes in developing a proprietary treatment for pediatric progressive myopia, addressing a significant global medical need. The company manufactures a topical eyedrop formulation aimed at treating this condition in children, allowing healthcare professionals to effectively manage and reduce the progression of myopia. Through its innovative approach, Sydnexis seeks to enhance eye care for pediatric patients and mitigate the prevalence of eye disorders in this demographic.
Rivus Pharmaceuticals is a biopharmaceutical company focused on enhancing cardio-metabolic health through the development of controlled metabolic accelerators (CMAs). These innovative therapeutics aim to improve cellular metabolism and target the root causes of prevalent metabolic and cardiovascular diseases. By providing oral small-molecule treatments, Rivus addresses critical metabolic risk factors associated with cardiovascular mortality and morbidity, thereby contributing to better health outcomes for patients suffering from these conditions.
Cortica Inc. is a healthcare company focused on providing neurological therapies for children with autism and other neurodevelopmental challenges. Established in 2014 and based in San Diego, California, Cortica offers personalized treatment programs that are tailored to each child's neurobiology and developmental profile. The company employs a multidisciplinary approach, utilizing insights from emerging neuroscience to deliver comprehensive care through in-home, in-clinic, and telehealth services. Its offerings include evidence-based therapies such as applied behavior analysis (ABA), speech therapy, and occupational therapy, all aimed at fostering independent living, educational opportunities, and social relationships for children with developmental differences. Cortica operates multiple centers in California, including locations in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village.
Ceribell, Inc. specializes in the design and manufacture of medical devices aimed at acquiring and interpreting electroencephalography (EEG) data for patients with neurological conditions. The company offers the Ceribell EEG System, which includes a versatile EEG headband accommodating various hair types and head sizes, and a compact, battery-operated EEG recorder that delivers clinical-quality data with an on-device display. Ceribell focuses on improving the accessibility and efficiency of EEG technology by developing an FDA-cleared instant EEG system that can be set up by any healthcare provider in just six minutes, eliminating the need for specialized technologists. This system features a unique Brain Stethoscope function that converts brainwaves into sound, allowing for the detection of seizures through auditory means. By facilitating earlier diagnoses and targeted treatments for seizures, including non-convulsive seizures, Ceribell aims to enhance patient outcomes while reducing risks such as mortality and complications. Founded in 2014 and based in Mountain View, California, Ceribell is committed to transforming the diagnosis and management of serious neurological conditions in acute care settings.
Cohere Health, Inc. is a software-as-a-service company based in Boston, Massachusetts, that focuses on enhancing the healthcare experience for patients, providers, and health plans. Incorporated in 2019, the company aims to improve the quality of care while reducing overall costs and increasing transparency throughout the patient care journey. Cohere Health specializes in intelligent prior authorization services, which are tailored to meet the specific needs of different health plans. By leveraging artificial intelligence, machine learning, and real-time analytics, the company automates the prior authorization process and facilitates collaboration between physicians and health plans. This approach not only streamlines the utilization management service but also promotes quality care across the entire patient journey.
Theseus Pharmaceuticals
Series B in 2021
Theseus Pharmaceuticals is a Technology based company.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.
Vera Therapeutics is engaged in the development of innovative gene editing solutions aimed at curing genetic diseases, particularly sickle cell disease and cystic fibrosis. The company utilizes a proprietary triplex gene editing platform to create a pipeline of therapeutic products targeting high-penetrance disease genes. Founded in 2016 and based in South San Francisco, California, Vera Therapeutics is dedicated to alleviating and potentially curing genetic disorders in affected patients.
Lexeo Therapeutics is a clinical-stage biotechnology company specializing in genetic medicines. The company develops adeno-associated virus (AAV)-mediated therapies, primarily in collaboration with Weill Cornell Medicine’s Department of Genetic Medicine. Its pipeline includes treatments for both rare and non-rare monogenic diseases, as well as hereditary and acquired conditions. Lexeo Therapeutics aims to address high unmet medical needs across various patient populations, focusing on both preclinical and clinical gene therapy candidates. The company is committed to advancing its clinical programs towards commercialization while maintaining research partnerships to enhance its preclinical pipeline.
Endeavor BioMedicines is a clinical-stage company focused on creating innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). The company is developing a small-molecule inhibitor aimed at addressing the underlying causes of this disease. This potential therapy not only seeks to halt the progression of IPF but may also reverse its effects, thereby providing healthcare professionals with precision treatment options for this terminal condition. By targeting the root causes of the disease, Endeavor BioMedicines aims to improve patient outcomes and enhance quality of life for those affected by pulmonary fibrosis.
Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression in organ transplant recipients. Its lead product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all long-term immunosuppression therapy within twelve months of their transplant. Additionally, the company's technology facilitates the safe administration of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, minimizing the risks associated with traditional methods. Founded in 1988 and based in Louisville, Kentucky, with an office in Wellesley, Massachusetts, Talaris Therapeutics has transitioned from its former name, Regenerex, Inc., in March 2019. The company is currently in the late stages of clinical development, also exploring applications for patients with severe autoimmune and immune-mediated disorders.
Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, that specializes in developing and selling innovative hearing aids for individuals experiencing hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, addressing common barriers to hearing aid adoption such as cost, accessibility, and social stigma. The company provides online hearing screenings and virtual support, allowing customers to receive assistance without needing in-person visits. Eargo's products are available for purchase online or over the phone, and the company emphasizes personalized consultations with licensed hearing professionals through various communication channels. By offering its solutions at approximately half the cost of traditional hearing aids, Eargo aims to enhance the quality of life for people with hearing impairments.
Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.
Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation.
The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Dascena, Inc. is a technology company based in Oakland, California, specializing in the development of algorithm software for diagnostics and biomarkers. Founded in 2018, Dascena creates machine learning algorithms designed to enhance early disease intervention and improve patient care outcomes. Its primary product, AlgoDiagnostics, autonomously processes electronic health record data to identify conditions such as acute decompensation, sepsis, and acute kidney injury. By leveraging advanced algorithms, Dascena aims to facilitate timely medical responses and support healthcare professionals in delivering better patient care.
AvengeBio is focusing on Cell-Generated Immunotherapies to eradicate solid tumors. It is a developer of a drug delivery platform intended to treat cancer. The company was founded in 2019 and based in Cambridge, Massachusetts.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that utilize innovative platforms such as XTEN for half-life extension, XPAT for protease-activated T cell engagement, and ProTIA for immuno-oncology applications. Amunix aims to develop therapies that can effectively activate the immune system to target solid tumors, thereby improving patient outcomes. The company collaborates with various partners in the biotechnology and pharmaceutical sectors to leverage its proprietary technologies across multiple therapeutic areas. Founded in 2006 and headquartered in Mountain View, California, Amunix is committed to advancing breakthrough therapies to combat cancer.
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.
Epirium Bio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases and metabolic syndrome. Established in 2008, the company has gained insights into mitochondrial biogenesis and function, leading to the discovery of a novel pharmacological approach for treating conditions associated with mitochondrial deficits. Epirium Bio has developed an intellectual property-protected platform of small molecules that represent a new class of therapeutics aimed at stimulating mitochondrial biogenesis and function. Their lead clinical candidate has demonstrated the ability to trigger mitochondrial biogenesis in early human studies and is being developed for various therapeutic areas, with an initial focus on rare diseases, neuromuscular, and neurodegenerative disorders. This innovative approach seeks to provide new treatment options for patients suffering from conditions such as muscular dystrophy.
Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative therapies for patients with significant unmet medical needs. The company is advancing a diverse pipeline that includes treatments for hematological malignancies and solid tumors, as well as liver-directed gene therapies aimed at rare diseases. Poseida is known for its proprietary gene engineering platforms, including the non-viral piggyBac DNA Modification System and the Cas-CLOVER site-specific gene editing system, which facilitate the creation of next-generation cell and gene therapeutics. Additionally, the company's portfolio encompasses CAR-T therapies for cancer and gene therapies targeting rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia. Founded in 2014, Poseida Therapeutics is committed to addressing critical health challenges through its advanced therapeutic solutions.
Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression in organ transplant recipients. Its lead product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all long-term immunosuppression therapy within twelve months of their transplant. Additionally, the company's technology facilitates the safe administration of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, minimizing the risks associated with traditional methods. Founded in 1988 and based in Louisville, Kentucky, with an office in Wellesley, Massachusetts, Talaris Therapeutics has transitioned from its former name, Regenerex, Inc., in March 2019. The company is currently in the late stages of clinical development, also exploring applications for patients with severe autoimmune and immune-mediated disorders.
Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.
Encore Dermatology is a privately held fully-integrated dermatology company that provides prescription therapies and medical devices to dermatologists. It provides a range of medical dermatology products, treating a number of topical disease states that enable patients to get improved skin care and treatment with ease. Encore Dermatology was established in 2015 and is headquartered in Malvern, Pennsylvania.
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.
Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.
KANDY THERAPEUTICS LIMITED develops non-hormonal treatment for multiple symptoms of the menopause including hot flashes and night time awakening. The company offers NT-814, a drug for common, chronic debilitating female sex-hormone related treatment. It provides non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment, and reduce symptoms of hormone related conditions. The company was founded in 2017 and is based in Stevenage, United Kingdom. KANDY THERAPEUTICS LIMITED operates as a subsidiary of Bayer Aktiengesellschaft.
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.
Sublimity Therapeutics (formerly Sigmoid Pharma), is a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California. Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s priority focus is on its lead product, STI-0529, for treatment of moderate to severe ulcerative colitis.
Murj is a Santa Cruz, California digital health company dedicated to helping clinicians streamline care for patients with implantable cardiac devices. Murj greets the challenge of managing the rapid growth of cardiac device data as an opportunity to improve care and deliver insight. Murj aims to liberate device clinics from paper reports and inadequate management tools, freeing clinicians to get back to the heart of the matter – their patients.
Neurana Pharmaceuticals, Inc. is a pharmaceutical company based in San Diego, California, focusing on the development of treatments for neuromuscular conditions. Founded in 2013, the company specializes in a novel therapeutic compound, Tolperisone, which addresses acute and painful muscle spasms in the neck and back as well as other musculoskeletal issues. Unlike traditional muscle relaxants, Tolperisone provides relief without causing sedation, offering a unique solution for patients experiencing spasticity and muscle discomfort.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative therapies for patients with significant unmet medical needs. The company is advancing a diverse pipeline that includes treatments for hematological malignancies and solid tumors, as well as liver-directed gene therapies aimed at rare diseases. Poseida is known for its proprietary gene engineering platforms, including the non-viral piggyBac DNA Modification System and the Cas-CLOVER site-specific gene editing system, which facilitate the creation of next-generation cell and gene therapeutics. Additionally, the company's portfolio encompasses CAR-T therapies for cancer and gene therapies targeting rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia. Founded in 2014, Poseida Therapeutics is committed to addressing critical health challenges through its advanced therapeutic solutions.
Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.
Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.
Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.
Cydan Development, Inc. is a company focused on the development and commercialization of therapies for orphan and rare diseases, with a particular emphasis on rare genetic disorders. Founded in 2012 and located in Lincoln, Massachusetts, Cydan functions as an orphan drug accelerator, identifying and de-risking compounds with therapeutic potential. The organization conducts comprehensive studies to support the further development of treatments by biotechnology firms. Cydan has worked on therapies for conditions such as Niemann-Pick Disease Type C and IMR-687 for sickle cell disease. The company leverages strong relationships with academic institutions and patient advocacy groups, along with deep expertise in drug development, to foster successful product commercialization and advance treatment options for underserved patient populations.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.
Amphora Medical, Inc. is a Minnesota-based company that develops medical devices focused on treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is working on a novel cystoscopic device designed to enhance bladder function and improve the quality of life for patients suffering from OAB. Utilizing minimally invasive procedures and advanced cystoscopic technology, Amphora Medical aims to provide effective solutions for individuals affected by this condition.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. The company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. Its flagship product, the Corus CAD test, is a blood-based gene expression test designed to help healthcare providers evaluate whether chest discomfort in non-diabetic patients is due to obstructive CAD. The company's innovations aim to improve treatment decisions, enhance patient outcomes, and reduce healthcare costs by providing actionable genomic information to clinicians. Established in 2003, CardioDx primarily serves customers across the United States.
Alphaeon Corporation is a company dedicated to the development of beauty, wellness, and lifestyle products for consumers in the United States and internationally. Incorporated in 2012 and headquartered in Irvine, California, Alphaeon offers a range of nutritional supplements, including Omega-3 products for skin and eye health, as well as beauty items designed to enhance the appearance of fine lines, wrinkles, and thinning eyelashes. The company also provides financing services for plastic surgery, ophthalmology, and dermatology procedures. By collaborating with board-certified physicians, Alphaeon aims to make innovative lifestyle healthcare products and services accessible to consumers, positioning itself as a leader in the self-pay healthcare sector. Its products are available for purchase online.
Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.
Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.
Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for the treatment of diseases affecting hospitalized patients. The company's primary product in development is ZOLYD, an investigational injectable antibiotic aimed at addressing serious and life-threatening infections caused by multi-drug resistant gram-negative and gram-positive bacteria. Founded in 2013, Zavante Therapeutics operates as a subsidiary of Nabriva Therapeutics plc, with a commitment to improving patient outcomes in critical care settings.
Velicept Therapeutics, Inc., a clinical development company, develops and commercializes drugs that have the potential to improve patients’ lives by transforming the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Its lead program include Solabegron, a differentiated and selective compound that relaxes the bladder smooth muscle by stimulating beta 3-adrenoceptors, which is being investigated for OAB and IBS conditions that affect the quality of life. The company was founded in 2015 and is based in Malvern, Pennsylvania.
BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and based in Goleta, California. The company specializes in developing non-surgical and non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a simple endoscopic procedure. This device helps patients feel full more quickly, prolongs the sensation of fullness, and delays gastric emptying, thereby supporting weight loss efforts.
Alphaeon Corporation is a company dedicated to the development of beauty, wellness, and lifestyle products for consumers in the United States and internationally. Incorporated in 2012 and headquartered in Irvine, California, Alphaeon offers a range of nutritional supplements, including Omega-3 products for skin and eye health, as well as beauty items designed to enhance the appearance of fine lines, wrinkles, and thinning eyelashes. The company also provides financing services for plastic surgery, ophthalmology, and dermatology procedures. By collaborating with board-certified physicians, Alphaeon aims to make innovative lifestyle healthcare products and services accessible to consumers, positioning itself as a leader in the self-pay healthcare sector. Its products are available for purchase online.
They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize eflornithine in North America.
The company was founded in 2012 and is headquartered in Palo Alto, California.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.
RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.
Alphaeon Corporation is a company dedicated to the development of beauty, wellness, and lifestyle products for consumers in the United States and internationally. Incorporated in 2012 and headquartered in Irvine, California, Alphaeon offers a range of nutritional supplements, including Omega-3 products for skin and eye health, as well as beauty items designed to enhance the appearance of fine lines, wrinkles, and thinning eyelashes. The company also provides financing services for plastic surgery, ophthalmology, and dermatology procedures. By collaborating with board-certified physicians, Alphaeon aims to make innovative lifestyle healthcare products and services accessible to consumers, positioning itself as a leader in the self-pay healthcare sector. Its products are available for purchase online.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in innovative solutions for aesthetic treatments. Founded in 2009, the company offers a diverse range of products, including Venus Versa, a multi-treatment platform for non-surgical procedures; Venus Legacy, designed for skin tightening and body contouring; and Venus Viva, a customizable skin resurfacing device. Additionally, Venus Concept provides Venus Freeze Plus for anti-aging and non-invasive skin tightening, and Venus Bliss for fat reduction. The company also features advanced hair restoration technologies, including NeoGraft and ARTAS robotic systems, which streamline the follicle harvesting process. Committed to ethical practices and technological advancement, Venus Concept aims to enhance the patient experience in the medical aesthetics industry.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.
Crownwheel Partners
Seed Round in 2013
Crownwheel Partners provides liquidity and financing solutions to royalty owners and companies in the global healthcare sector. Founded in 2013, CrownWheel invests in commercial and late-stage products through the full or partial monetization of royalty streams, revenue participation, the purchase of structured debt and equity, and the acquisition of legacy or non-core products.
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
Practice Fusion, Inc. is a cloud-based electronic health records (EHR) company based in San Francisco, California. Founded in 2005, it provides a practice management software platform that includes features such as charting, scheduling, billing, e-Prescribing, lab integrations, and secure messaging. The platform aims to connect a wide range of stakeholders in the healthcare ecosystem, including medical professionals, patients, labs, billers, imaging centers, and life science partners. Additionally, Practice Fusion offers Practice Fusion Insight, a healthcare database designed for medical professionals. The company serves a diverse clientele, including independent practices, small and large medical groups, community organizations, and non-profits. In 2018, Practice Fusion became a subsidiary of Allscripts Healthcare Solutions, further enhancing its capabilities in the electronic health records space.
PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.
Sympara Medical
Seed Round in 2013
Sympara Medical is a medical company that focuses on developing novel therapies for hypertension. It was established in 2012 and is based in San Francisco, California.
Private Equity Round in 2012
CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. The company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. Its flagship product, the Corus CAD test, is a blood-based gene expression test designed to help healthcare providers evaluate whether chest discomfort in non-diabetic patients is due to obstructive CAD. The company's innovations aim to improve treatment decisions, enhance patient outcomes, and reduce healthcare costs by providing actionable genomic information to clinicians. Established in 2003, CardioDx primarily serves customers across the United States.
Private Equity Round in 2012
CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. The company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. Its flagship product, the Corus CAD test, is a blood-based gene expression test designed to help healthcare providers evaluate whether chest discomfort in non-diabetic patients is due to obstructive CAD. The company's innovations aim to improve treatment decisions, enhance patient outcomes, and reduce healthcare costs by providing actionable genomic information to clinicians. Established in 2003, CardioDx primarily serves customers across the United States.
Aptus Endosystems, Inc. is a medical device company focused on developing, manufacturing, and distributing innovative solutions for endovascular aneurysm repair (EVAR). Established in 2002 and headquartered in Sunnyvale, California, the company specializes in advanced technologies for treating aortic aneurysms, particularly through its Heli-FX EndoAnchor system, which provides a durable alternative to open surgical repair. This system utilizes unique helical staple technology for effective endograft fixation, enabling minimally invasive treatment options that maintain the control associated with open surgery. Aptus also offers the Aptus TourGuide, a steerable sheath designed for efficient access and delivery of peripheral vascular products. The company's products are available in several countries, including the United States, Germany, Italy, the Netherlands, and the United Kingdom, primarily through distributors.
Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating chronic pain while addressing the concerns of prescription drug abuse. The company utilizes its patented DETERx platform technology to create abuse-deterrent formulations that maintain the extended-release profiles and safety of medications despite potential misuse methods such as chewing or crushing. Collegium's product lineup includes Xtampza ER, an extended-release oral formulation of oxycodone designed to deter abuse, as well as Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol respectively, for managing severe pain and acute pain in adults. Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium focuses on delivering innovative solutions for patients with chronic pain, utilizing formulation improvements backed by strong intellectual property protections.
Private Equity Round in 2011
CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, focused on developing genomic tests for cardiovascular diseases. The company specializes in assessing conditions such as coronary artery disease (CAD), cardiac arrhythmias, and heart failure. Its flagship product, the Corus CAD test, is a blood-based gene expression test designed to help healthcare providers evaluate whether chest discomfort in non-diabetic patients is due to obstructive CAD. The company's innovations aim to improve treatment decisions, enhance patient outcomes, and reduce healthcare costs by providing actionable genomic information to clinicians. Established in 2003, CardioDx primarily serves customers across the United States.
PixelOptics was founded in 2005 as the world's first composite lens company. Their unique and proprietary approach to lens design combines sound lens design principles and well-known, proven lens materials to create entirely new categories of eyeglass lenses.
Civitas Therapeutics is a biopharmaceutical company dedicated to developing therapies for pulmonary delivery. The company focuses on creating innovative treatments for central nervous system and respiratory disorders, with a particular emphasis on conditions such as multiple sclerosis and spinal cord injuries. Civitas Therapeutics aims to improve the health and quality of life for patients across the United States through its specialized drug delivery systems.
Aptus Endosystems, Inc. is a medical device company focused on developing, manufacturing, and distributing innovative solutions for endovascular aneurysm repair (EVAR). Established in 2002 and headquartered in Sunnyvale, California, the company specializes in advanced technologies for treating aortic aneurysms, particularly through its Heli-FX EndoAnchor system, which provides a durable alternative to open surgical repair. This system utilizes unique helical staple technology for effective endograft fixation, enabling minimally invasive treatment options that maintain the control associated with open surgery. Aptus also offers the Aptus TourGuide, a steerable sheath designed for efficient access and delivery of peripheral vascular products. The company's products are available in several countries, including the United States, Germany, Italy, the Netherlands, and the United Kingdom, primarily through distributors.
Helomics is a personalized healthcare company based in Pittsburgh, Pennsylvania, specializing in oncology insights and contract research services. The company focuses on six primary cancers: ovarian, breast, pancreatic, colon, lung, and brain. Helomics utilizes its Precision Cellular Analytical Platform and advanced bioinformatics to deliver personalized tumor profiles, aiding physicians in making informed treatment decisions. Its portfolio includes ChemoFx, which helps in selecting effective treatments for gynecologic cancer, and various biomarker tests like BioSpeciFx and GeneFx, designed to evaluate patient tumors at a molecular level. Additionally, Helomics offers tumor profiling services, patient-derived tumor models, and multi-omics assays, enhancing the precision of cancer care. The company collaborates with pharmaceutical and diagnostic firms to improve patient outcomes through tailored diagnostic solutions and insights, ultimately supporting better clinical decision-making in oncology.
AqueSys, Inc. is an ophthalmic company based in Aliso Viejo, California, that specializes in developing and commercializing innovative implantable devices for glaucoma treatment. The company's primary product, the XEN gel stent, facilitates the outflow of aqueous humor from the anterior chamber to the subconjunctival space, effectively lowering intraocular pressure in patients with glaucoma. Established in 2005, AqueSys operates as a subsidiary of Allergan plc, focusing on addressing the challenges associated with managing glaucoma through its advanced medical technology. The XEN gel stent represents a significant advancement in glaucoma treatment, providing an alternative pathway for excess fluid to exit the eye and enhancing patient outcomes.
Solta Medical, Inc. specializes in designing, developing, manufacturing, and marketing energy-based medical devices focused on aesthetic applications. The company offers a range of products, including the Thermage NXT system for non-invasive skin tightening and contouring, and the Fraxel series of systems that treat various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. Their devices incorporate advanced technology with handpieces, user-friendly consoles, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and general practitioners, and distributes its products through a direct sales force and a network of international distributors. Founded in 1995 and headquartered in Hayward, California, the company was previously known as Thermage, Inc. before rebranding in 2009.
Solta Medical, Inc. specializes in designing, developing, manufacturing, and marketing energy-based medical devices focused on aesthetic applications. The company offers a range of products, including the Thermage NXT system for non-invasive skin tightening and contouring, and the Fraxel series of systems that treat various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. Their devices incorporate advanced technology with handpieces, user-friendly consoles, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and general practitioners, and distributes its products through a direct sales force and a network of international distributors. Founded in 1995 and headquartered in Hayward, California, the company was previously known as Thermage, Inc. before rebranding in 2009.
Velomedix, Inc. is a therapeutic hypothermia company based in Menlo Park, California. The company specializes in technologies designed to protect the body’s organs during ischemic or inflammatory insults. Velomedix's innovative approach aims to provide an effective solution for preserving organ function in critical medical situations.
Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening.
Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
Amarin Corporation plc is a pharmaceutical company dedicated to developing and commercializing therapeutics for cardiovascular diseases in the United States. Its primary product, Vascepa, is a prescription omega-3 fatty acid capsule designed to reduce triglyceride levels in adults with severe hypertriglyceridemia. The company is also conducting research on the REDUCE-IT study, which targets patients with high triglyceride levels who are undergoing statin therapy. Amarin markets its products primarily to wholesalers and specialty pharmacy providers, utilizing a direct sales force. The company has partnered with Mochida Pharmaceutical Co., Ltd. to further develop and commercialize products based on the active ingredient in Vascepa, eicosapentaenoic acid. Founded in 1989 and headquartered in Dublin, Ireland, Amarin has a research and development facility in Mystic, Connecticut, and focuses on lipid science to enhance cardiovascular disease management.
Jazz Pharmaceuticals is a biopharmaceutical company specializing in the identification, development, and commercialization of products for neurology and psychiatry, primarily in the United States. The company's notable products include Xyrem, which treats cataplexy and excessive daytime sleepiness in narcolepsy patients; Cystadane, for homocystinuria; and Antizol, used for ethylene glycol and methanol poisoning. Jazz Pharmaceuticals is advancing several late-stage candidates such as Luvox CR, an extended-release formulation for obsessive-compulsive disorder and social anxiety disorder, and JZP-6, a liquid form of sodium oxybate aimed at treating fibromyalgia. Its clinical pipeline features JZP-4, targeting epilepsy and bipolar disorder; JZP-8, for acute seizure clusters; JZP-7, for restless legs syndrome; and JZP-2, designed for panic attacks in panic disorder. The company maintains a product development and licensing agreement with Antares Pharma. Founded in 2003, Jazz Pharmaceuticals is headquartered in Palo Alto, California.